PhaseRx (PhaseRx) Interest Expense : $-0.94 Mil (TTM As of Sep. 2017)

View and export this data going back to 2016. Start your Free Trial

What is PhaseRx Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. PhaseRx's interest expense for the three months ended in Sep. 2017 was $ -0.23 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2017 was $-0.94 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. PhaseRx's Operating Income for the three months ended in Sep. 2017 was $ -2.54 Mil. PhaseRx's Interest Expense for the three months ended in Sep. 2017 was $ -0.23 Mil. PhaseRx did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

PhaseRx Interest Expense Historical Data

The historical data trend for PhaseRx's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhaseRx Interest Expense Chart

PhaseRx Annual Data

Trend

Dec14

Dec15

Dec16

Interest Expense

-1.37

-1.65

-2.06

PhaseRx Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17
Interest Expense	Get a 7-Day Free Trial							-0.23	-0.24	-0.24	-0.24	-0.23

PhaseRx Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.94 Mil.

PhaseRx (OTCPK:PZRXQ) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

PhaseRx's Interest Expense for the three months ended in Sep. 2017 was $-0.23 Mil. Its Operating Income for the three months ended in Sep. 2017 was $-2.54 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2017 was $3.61 Mil.

PhaseRx's Interest Coverage for the quarter that ended in Sep. 2017 is calculated as

PhaseRx did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

PhaseRx (PhaseRx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PhaseRx Inc (OTCPK:PZRXQ) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

410 West Harrison Street, Suite 300, Seattle, WA, USA, 98119

Website

http://www.phaserx.com

PhaseRx Inc is a biopharmaceutical company. It is developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, or i-ERT. The approach is enabled by proprietary Hybrid messenger RNA, or mRNA, Technology platform, which allows synthesis of the missing enzyme inside the cell. The product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency, or OTCD, argininosuccinate lyase deficiency, or ASL deficiency, and argininosuccinate synthetase deficiency, or ASS1 deficiency.

Executives

Gordon Brandt	officer: Chief Medical Officer	410 WEST HARRISON STREET, SEATTLE WA 98119
Paul H Johnson	director	3450 MONTE VILLA PARKWAY, BOTHELL WA 98053
Peggy V Phillips	director	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
Michelle Renee Griffin	director	19723 NE 65TH LANE, KIRKLAND WA 98033
Brian G Atwood	director, 10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Schmidt John A Jr	director	300 THIRD ST, CAMBRIDGE X1 02142
Steven Gillis	director, 10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Samuel D Colella	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Robert Nelsen	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Rebecca B Robertson	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Barbara N Lubash	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Donald B Milder	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Charles M Warden	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Side Fund Iii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Venture Capital Iii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104

PhaseRx (PhaseRx) Headlines

From GuruFocus

PhaseRX: The Latest Pick From a Legendary VC Firm

By $$$ Christopher Malcolm • 05-24-2016

Stocks Open Higher in Friday Session

By Omar Venerio Omar Venerio • 10-13-2017